Carthamoleusterone



Compound IDCDAMM02868
Common nameCarthamoleusterone
IUPAC name2,3,11,14-tetrahydroxy-17-[3-hydroxy-5-(hydroxymethyl)-2-methyl-5-propan-2-yloxolan-2-yl]-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one
Molecular formulaC28H44O8

Experimental data

Retention time11.97
Adduct[M+H]+
Actual mz509.311
Theoretical mz509.311
Error0.93
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score5.9022

Identifiers and class information

Inchi keyKFWPEZQKCIZSHF-VPXXDOQGNA-N
SmilesO=C1C=C2C(C(O)CC3(C)C(CCC23O)C4(OC(CO)(CC4O)C(C)C)C)C5(C)CC(O)C(O)CC15
SuperclassLipids and lipid-like molecules
ClassSteroids and steroid derivatives

Pharmacokinetic properties

Number of descriptor values(#stars)1
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)8
Number of reactive functional groups (#rtvFG)0
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)508.651
Computed dipole moment(dipole)6.305
Total solvent accessible surface area (SASA)707.162
Hydrophobic component of SASA (FOSA)446.664
Hydrophilic component of SASA (FISA)248.356
Pie component of the SASA (PISA)12.142
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1452.94
Number of hydrogen bond donors (donorHB)6
Number of hydrogen bond acceptors (accptHB)12
Free energy of solvation of dipole (dip^2/V)0.0273566
Index of cohesive interaction in solids (ACxDN^.5/SA)0.041566
Globularity descriptor (glob)0.87729
Predicted polarizability in cubic angstroms (QPpolrz)46.972
Predicted hexadecane/gas partition coefficient (QPlogPC16)14.762
Predicted octanol/gas partition coefficient (QPlogPoct)31.62
Predicted water/gas partition coefficient (QPlogPw)22.036
Predicted octanol/water partition coefficient (QPlogPo/w)1.27
Predicted aqueous solubility (QPlogS)-3.778
Conformation-independent predicted aqueous solubility (CIQPlogS)-4.643
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-3.575
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)43.726
Predicted brain/blood partition coefficient (QPlogBB)-2.07
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)16.794
Predicted skin permeability, log Kp (QPlogKp)-5.286
PM3 calculated ionization potential (IP(ev))10.108
PM3 calculated electron affinity (EA(eV))0.34
Number of likely metabolic reactions (#metab)9
Prediction of binding to human serum albumin (QPlogKhsa)-0.02
Predicted qualitative human oral absorption (HumanOralAbsorption)2
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)37.83
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)143.789
Number of nitrogen and oxygen atoms (#NandO)8
Number of violations of Lipinski’s rule of five (RuleOfFive)2
Number of violations of Jorgensen’s rule of three (RuleOfThree)1

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P20309CHRM3Muscarinic acetylcholine receptor M3T67684SwissTargetPrediction
P04818TYMSThymidylate synthase (by homology)T98397SwissTargetPrediction
Q8TDS4HCAR2Hydroxycarboxylic acid receptor 2T88185SwissTargetPrediction
P42336PIK3CAPI3-kinase p110-alpha subunitT80276SwissTargetPrediction
P43405SYKTyrosine-protein kinase SYKT62431SwissTargetPrediction
Q8IXJ6SIRT2NAD-dependent deacetylase sirtuin 2T83904SwissTargetPrediction
P08473MMENeprilysinT05409SwissTargetPrediction
P17612PRKACAcAMP-dependent protein kinase alpha-catalytic subunitT12808SwissTargetPrediction
P10275ARAndrogen ReceptorT11211SwissTargetPrediction
P06401PGRProgesterone receptorT22939SwissTargetPrediction
P07339CTSDCathepsin DT67102SwissTargetPrediction
P18031PTPN1Protein-tyrosine phosphatase 1BT16347SwissTargetPrediction
P28845HSD11B111-beta-hydroxysteroid dehydrogenase 1T65200SwissTargetPrediction
P42345MTORSerine/threonine-protein kinase mTORT75243SwissTargetPrediction
O14965AURKASerine/threonine-protein kinase Aurora-AT87675SwissTargetPrediction
P08172CHRM2Muscarinic acetylcholine receptor M2T46185SwissTargetPrediction
P01375TNFTNF-alphaT20178SwissTargetPrediction
P42892ECE1Endothelin-converting enzyme 1T50970SwissTargetPrediction
P23109AMPD1AMP deaminase 1T84553SwissTargetPrediction
Q99808SLC29A1Equilibrative nucleoside transporter 1T13491SwissTargetPrediction
P04629NTRK1Nerve growth factor receptor Trk-AT07173SwissTargetPrediction
P49840GSK3AGlycogen synthase kinase-3 alphaT76910SwissTargetPrediction
P31639SLC5A2Sodium/glucose cotransporter 2T30085SwissTargetPrediction
P55085F2RL1Proteinase-activated receptor 2T62841SwissTargetPrediction
P37023ACVRL1Serine/threonine-protein kinase receptor R3T36959SwissTargetPrediction
P23109AMPD1AMP deaminase 1T84553SwissTargetPrediction
Q9HBA0TRPV4Transient receptor potential cation channel subfamily V member 4T64213SwissTargetPrediction

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T67684DI0037Asthma[ICD-11: CA23]P20309CHRM3
T67684DI0086Chronic obstructive pulmonary disease[ICD-11: CA22]P20309CHRM3
T67684DI0154Functional bladder disorder[ICD-11: GC50]P20309CHRM3
T67684DI0166Glaucoma[ICD-11: 9C61]P20309CHRM3
T67684DI0293Nausea/vomiting[ICD-11: MD90]P20309CHRM3
T67684DI0333Peptic ulcer[ICD-11: DA61]P20309CHRM3
T67684DI0362Respiratory system disease[ICD-11: CB40-CB7Z]P20309CHRM3
T67684DI0371Sebaceous gland disorder[ICD-11: ED91]P20309CHRM3
T67684DI0382Sjogren syndrome[ICD-11: 4A43]P20309CHRM3
T67684DI0411Tonus and reflex abnormality[ICD-11: MB47]P20309CHRM3
T98397DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P04818TYMS
T98397DI0395Stomach cancer[ICD-11: 2B72]P04818TYMS
T88185DI0203Inborn lipid metabolism error[ICD-11: 5C52]Q8TDS4HCAR2
T80276DI0062Breast cancer[ICD-11: 2C60-2C6Y]P42336PIK3CA
T80276DI0151Follicular lymphoma[ICD-11: 2A80]P42336PIK3CA
T80276DI0245Malignant haematopoietic neoplasm[ICD-11: 2B33]P42336PIK3CA
T62431DI0403Thrombocytopenia[ICD-11: 3B64]P43405SYK
T83904DI0365Retinopathy[ICD-11: 9B71]Q8IXJ6SIRT2
T05409DI0175Heart failure[ICD-11: BD10-BD1Z]P08473MME
T12808DI0279Muscular atrophy[ICD-11: 8B61]P17612PRKACA
T11211DI0005Acne vulgaris[ICD-11: ED80]P10275AR
T11211DI0012Acute myeloid leukaemia[ICD-11: 2A60]P10275AR
T11211DI0021Alcoholic liver disease[ICD-11: DB94]P10275AR
T11211DI0062Breast cancer[ICD-11: 2C60-2C6Y]P10275AR
T11211DI0086Chronic obstructive pulmonary disease[ICD-11: CA22]P10275AR
T11211DI0145Female pelvic pain[ICD-11: GA34]P10275AR
T11211DI0194Hypo-osmolality/hyponatraemia[ICD-11: 5C72]P10275AR
T11211DI0237Low bone mass disorder[ICD-11: FB83]P10275AR
T11211DI0247Mammary tumour[ICD-11: 2C60-2C6Z]P10275AR
T11211DI0346Prostate cancer[ICD-11: 2C82]P10275AR
T11211DI0401Testicular dysfunction[ICD-11: 5A81]P10275AR
T22939DI0062Breast cancer[ICD-11: 2C60-2C6Y]P06401PGR
T22939DI0100Contraceptive management[ICD-11: QA21]P06401PGR
T22939DI0255Menstrual cycle bleeding disorder[ICD-11: GA20]P06401PGR
T22939DI0344Preterm labour/delivery[ICD-11: JB00]P06401PGR
T22939DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P06401PGR
T67102DI0275Multiple sclerosis[ICD-11: 8A40]P07339CTSD
T16347DI0009Acute diabete complication[ICD-11: 5A2Y]P18031PTPN1
T16347DI0062Breast cancer[ICD-11: 2C60-2C6Y]P18031PTPN1
T16347DI0308Obesity[ICD-11: 5B80-5B81]P18031PTPN1
T16347DI0417Type 2 diabetes mellitus[ICD-11: 5A11]P18031PTPN1
T65200DI0210Influenza[ICD-11: 1E30-1E32]P28845HSD11B1
T65200DI0239Lupus erythematosus[ICD-11: 4A40]P28845HSD11B1
T65200DI0417Type 2 diabetes mellitus[ICD-11: 5A11]P28845HSD11B1
T75243DI0036Arteries/arterioles disorder[ICD-11: BD52]P42345MTOR
T75243DI0085Chronic myelomonocytic leukaemia[ICD-11: 2A40]P42345MTOR
T75243DI0274Multiple myeloma[ICD-11: 2A83]P42345MTOR
T75243DI0361Renal cell carcinoma[ICD-11: 2C90]P42345MTOR
T75243DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P42345MTOR
T75243DI0413Transplant rejection[ICD-11: NE84]P42345MTOR
T87675DI0009Acute diabete complication[ICD-11: 5A2Y]O14965AURKA
T87675DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]O14965AURKA
T46185DI0037Asthma[ICD-11: CA23]P08172CHRM2
T46185DI0166Glaucoma[ICD-11: 9C61]P08172CHRM2
T46185DI0278Muscle disorder[ICD-11: FB32-FB3Z]P08172CHRM2
T46185DI0333Peptic ulcer[ICD-11: DA61]P08172CHRM2
T46185DI0362Respiratory system disease[ICD-11: CB40-CB7Z]P08172CHRM2
T46185DI0371Sebaceous gland disorder[ICD-11: ED91]P08172CHRM2
T20178DI0035Arterial occlusive disease[ICD-11: BD40]P01375TNF
T20178DI0274Multiple myeloma[ICD-11: 2A83]P01375TNF
T20178DI0351Psoriasis[ICD-11: EA90]P01375TNF
T20178DI0366Rheumatoid arthritis[ICD-11: FA20]P01375TNF
T13491DI0030Angina pectoris[ICD-11: BA40]Q99808SLC29A1
T07173DI0303Non-small-cell lung cancer[ICD-11: 2C25]P04629NTRK1
T07173DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P04629NTRK1
T76910DI0134Epilepsy/seizure[ICD-11: 8A61-8A6Z]P49840GSK3A
T30085DI0120Diabetes mellitus[ICD-11: 5A10]P31639SLC5A2
T30085DI0175Heart failure[ICD-11: BD10-BD1Z]P31639SLC5A2
T30085DI0417Type 2 diabetes mellitus[ICD-11: 5A11]P31639SLC5A2
T62841DI0087Chronic pain[ICD-11: MG30]P55085F2RL1
T36959DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P37023ACVRL1
T64213DI0012Acute myeloid leukaemia[ICD-11: 2A60]Q9HBA0TRPV4
T64213DI0175Heart failure[ICD-11: BD10-BD1Z]Q9HBA0TRPV4
T64213DI0183Hodgkin lymphoma[ICD-11: 2B30]Q9HBA0TRPV4

Copyright © 2025